October 8, 2025

Vivace Therapeutics’ VT3989 Granted Fast Track Designation by the U.S. Food and Drug Administration for the Treatment of Mesothelioma

Research and Publications

The Hippo Pathway and Human Cancer

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics